Canine leukocyte adhesion deficiency (CLAD) provides a unique large animal model for testing new therapeutic approaches for the treatment of children with leukocyte adhesion deficiency (LAD). In our CLAD model, we examined two different fragments of the human elongation factor 1a (EF1a) promoter (EF1aL, 1189 bp and EF1aS, 233 bp) driving the expression of canine CD18 in a self-inactivating (SIN) lentiviral vector. The EF1aS vector resulted in the highest levels of canine CD18 expression in CLAD CD34 + cells in vitro. Subsequently, autologous CD34 + bone marrow cells from four CLAD pups were transduced with the EF1aS vector and infused following a non-myeloablative dose of 200 cGy total-body irradiation. None of the CLAD pups achieved levels of circulating CD18 + neutrophils sufficient to reverse the CLAD phenotype, and all four animals were euthanized because of infections within 9 weeks of treatment. These results indicate that the EF1aS promoter-driven CD18 expression in the context of a RRLSIN lentiviral vector does not lead to sufficient numbers of CD18 + neutrophils in vivo to reverse the CLAD phenotype when used in a nonmyeloablative transplant regimen in dogs.
Introduction
Canine leukocyte adhesion deficiency (CLAD), the canine homologue of leukocyte adhesion deficiency (LAD)-I in humans, is characterized by severe, recurrent bacterial infections leading to death within the first 6 months of life.
1,2 CLAD animals are homozygous for the identical 107G4C nucleotide substitution in the CD18 coding sequence, which results in a C36S amino acid substitution in the CD18 protein. 3 In previous studies, we used the CLAD model to demonstrate that both g-retroviral and foamy viral vector-mediated transfer of the canine CD18 cDNA can reverse the CLAD phenotype. 4, 5 However, both studies relied on the long terminal repeat (LTR) of the murine stem cell virus (MSCV) promoter to express the canine CD18 cDNA; in the g-retroviral vector, the MSCV 5 0 LTR directed the expression of canine CD18, whereas in the foamy viral vector, an internal MSCV LTR promoter fragment directed canine CD18 expression. 4, 5 Recently, insertional mutagenesis from retroviral promoters, particularly the murine leukemia virus LTR promoter/enhancer, has emerged as a serious concern in hematopoietic stem cell gene therapy. In the gene therapy clinical trials for the treatment of X-linked severe combined immunodeficiency disease, and chronic granulomatous disease, insertional activation of nearby proto-oncogenes by a strong retroviral LTR promoter led to leukemia and myelodysplastic syndrome, respectively. 6, 7 Subsequent research has demonstrated that replacement of retroviral LTR promoters by cellular promoters may reduce the risk of insertional activation from viral promoters/enhancers. 8 The human elongation factor 1a (EF1a) has been shown to direct the expression of reporter genes in a variety of cell types, including neural and lymphoid cells. 9 The EF1a promoter (nucleotides 373-1561) has also been shown to be a strong promoter in primary human CD34 + cells. [10] [11] [12] [13] When used within the context of a selfinactivating (SIN) lentiviral vector, EF1a promoterdriven enhanced green fluorescent protein expression was comparable with that of the MSCV LTR, the phosphoglycerate kinase promoter, and the composite CAG promoter (consisting of the cytomegalovirus immediate early enhancer and the chicken b-actin promoter) in the human myeloid leukemia cell line, KG-1a. 12 In addition, the EF1a promoter has been shown to induce ubiquitous and high-level expression of human CD55 and CD59 in transgenic rabbits. 14 The studies described above prompted us to test the efficacy of the human EF1a cellular promoter in a SIN lentiviral vector to direct canine CD18 expression in dogs with CLAD.
Results and discussion
We constructed human immunodeficiency virus-based SIN lentiviral vectors expressing canine CD18 from two different lengths of the human EF1a promoter/enhancer-a 233 bp fragment consisting of nucleotides from 378 to 610 (EF1aS) and a 1189 bp fragment consisting of nucleotides from 373 to 1561 (EF1aL) 12, 13 ( Figure 1a ). As a control, an MSCV promoter driving expression of canine CD18 was also constructed using the same lentiviral vector backbone, pRRLSIN.cPPT.WPRE. Lentiviral vectors were pseuodotyped with a vesicular stomatitis virus G-glycoprotein envelope.
The CD18 subunit does not become surface expressed without the CD11 subunit; therefore, we used an EpsteinBarr virus (EBV)-transformed B-cell line derived from a LAD patient (ZJ) to determine the expression of CD18 from the three vectors. The ZJ LAD EBV B-cell line expresses the endogenous human CD11a leukocyte integrin subunit, but does not express the human CD18 subunit. 15 Transduction of normal human or canine CD18 into LAD EBV B-cells has been shown previously to rescue the CD11a subunits and result in surface expression of the CD11a-CD18 complexes. + cells served as negative and positive controls, respectively. The EF1aS vector yielded higher transduction efficiencies (5.8 and 11.5%, at multiplicities of infections of 10 and 100, respectively) than the EF1aL vector (4.9 and 6.1%). Again, the MSCV vector resulted in the highest percentage of CD18 + cells (12 and 15.1%) (Figure 2a) . Analysis of the mean fluorescence intensity based on CD18 expression in vector-transduced CD34 + cells indicated that the expression of CD18 from both the EF1a promoters were comparable, and similar to the CD18 expression in CD34 + cells from a normal dog (Figure 2b) . The MSCV vector generated higher levels of CD18 expression than that observed on normal canine CD34 + cells (Figure 2b ). To assess the ability of the EF1aS promoter within the context of a SIN lentiviral vector to direct canine CD18 expression on leukocytes in vivo, we used this vector in an ex vivo gene therapy protocol that we had used previously to test foamy viral vectors in the treatment of CLAD. 5 We selected the EF1aS vector because of its higher titer and higher transduction efficiency in CLAD Abbreviations: CLAD, canine leukocyte adhesion deficiency; EF, elongation factor; LTR, long terminal repeat; MSCV, murine stem cell virus; PBL, peripheral blood leukocyte. Lentiviral vector used the EF1aS promoter to express canine CD18 cDNA; foamy viral vector used the MSCV internal promoter to express canine CD18 cDNA; and g-retroviral vector used the MSCV LTR to express canine CD18 cDNA. *Timepoint before death. Figure 3 (a) Genomic PCR from PBLs for canine CD18 cDNA integration. Genomic DNA was isolated from PBLs 8 weeks (3 weeks for dog (LV4) after infusion of vector-transduced cells for the LV1À4 and at 12 weeks after infusion for the foamy viral vector (FV1À4) and the g-retroviral vector (RV1,2). In all, 100 ng of genomic DNA was used as a template to assess the integration of canine CD18 cDNA by PCR. Std, 100-bp size standard; CLAD, untreated CLAD dog. 
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Surface expression of CD18 was assessed on peripheral blood leukocytes before infusion, and at weekly intervals following infusion. We had previously demonstrated that even low levels (0.5%) of CD18 + peripheral blood leukocytes (PBLs) could reverse or attenuate the CLAD phenotype. 17, 18 However, none of the EF1aS promoter lentiviral vector-treated dogs had greater than 0.3% CD18 + PBLs at any time after infusion, and all four succumbed to infection by 9 weeks after treatment.
Despite the very low levels of CD18 + leukocytes in the peripheral blood after the infusion of vector-transduced autologous CD34
+ cells, vector-integrated CD18 cDNA could be amplified readily from the genomic DNA extracted from the PBLs of all four dogs, suggesting that the amount of the vector DNA present in the PBLs of the treated dogs did not correlate with very low levels of surface CD18 expression (Figure 3a) .
Previously, we reported that ex vivo gene therapy in CLAD CD34
+ cells using a g-retroviral vector with the MSCV LTR, and a foamy virus vector incorporating the MSCV internal promoter, resulted in sufficient surface expression of canine CD18 to reverse the CLAD phenotype using the same non-myeloablative conditioning regimen of 200 cGy TBI used in this study. 4, 5 In this study, the human EF1aS promoter (EF1a promoter without intron 1) within the context of a SIN lentiviral vector did not result in sufficient numbers of CD18 + neutrophils in vivo to reverse the CLAD phenotype.
To investigate this failure of the EF1aS promoter in a lentiviral vector to reverse the CLAD phenotype, we compared the differences of the lentiviral vector with the foamy viral vector and the g-retroviral vector (Table 1) . Although the transduction efficiency of the foamy viral vector and the g-retroviral vector were higher than the lentiviral vector, comparable numbers of CD18 + CD34 + cells per kg were infused because of the higher numbers of CD34 + cells used with the lentiviral vector-treated animals (Table 1) . Also, the percentages of CD18 + PBLs were only slightly higher in the g-retroviral vector treated dogs compared with the lentiviral vector-treated animals. The amount of DNA copies of CD18 cDNA were nearly commensurate with the levels seen in the g-retroviral vector-treated animals in three lentiviral vector-treated dogs, and actually exceeded the levels seen in the g-retroviral vector-treated dogs in one case namely, LV1 (Figure 3a) .
To pursue this question of whether the EF1aS promoter in the lentiviral vector might lose activity over time, we compared CLAD CD34 + cells transduced with the EF1aS promoter in the lentiviral vector to CLAD CD34 + cells transduced with the MSCV promoter in the same lentiviral vector backbone, and to CLAD CD34 + cells transduced with the foamy viral vector incorporating an internal MSCV promoter (Figure 3b ). CD18 + expression at two time points was compared: on day 5 after the 16 h transduction, and on day 15 after transduction and further incubation with growth factors (cG-CSF, c-SCF and Flt3 ligand). There was a marked decrease in CD18 expression in CD34 + cells transduced with the EF1aS vector compared with the MSCV lentiviral vector after the 2-week expansion (Figure 3b) . This raises the question as to whether the EF1aS promoter in the lentiviral vector is being silenced. There is evidence that the EF1aS promoter in a lentiviral vector is prone to transcriptional gene silencing. 19 Our future studies are directed towards improving vector design and efficiency of transduction, as well as identifying other cellular promoters capable of directing consistent, stable and therapeutically relevant levels of CD18 expression in vivo.
